XML 73 R58.htm IDEA: XBRL DOCUMENT v3.23.1
Related Parties Transactions (Details) - USD ($)
1 Months Ended 12 Months Ended
May 08, 2020
Jun. 16, 2022
Jul. 19, 2017
Feb. 24, 2015
Dec. 31, 2022
Dec. 31, 2021
Nov. 30, 2022
Dec. 01, 2021
Sep. 30, 2021
Sep. 07, 2021
Jul. 01, 2020
Related Parties Transactions (Details) [Line Items]                      
Due from rgene amounted           $ 1,889          
Discount of stock price           12.00%          
Balance of outstanding loans         $ 500,000 $ 33,520          
Accrued interest           13,701          
Related parties transactions, description   the Company entered into a one-year convertible loan agreement with Rgene, with a principal amount of $1,000,000 to Rgene which bears interest at 5% per annum for the use of working capital that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene. The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note. The Note includes standard events of default, as well as a cross-default provision pursuant to which a breach of the Service Agreement will trigger an event of default under the convertible note if not cured after 5 business days of written notice regarding the breach is provided.                  
Interest rate percentage             6.50%        
Maturity date     Jul. 18, 2019                
Due amount         112,822 124,972          
Aggregated amount $ 150,000                    
Advanced amount $ 150,000                    
Outstanding principal and accrued interest         151,450 168,131          
Interest expenses         21,378 22,779          
BioFirst (Australia) [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Aggregate working capital         $ 275,901 132,443          
Minimum [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Interest rate         12.00%            
Ownership percentage         0.00%            
Maximum [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Interest rate         13.6224%            
Ownership percentage         1.00%            
Rgene [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Due from rgene amounted           $ 49,110          
Interest rate           1.00%          
Accrued interest         $ 13,819            
BioFirst (Australia) [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Accrued interest         $ 1,028,556 $ 491,816          
Due from rgene amounted               $ 250,000     $ 361,487
Interest rate percentage                 6.50%    
Total loan amount                   $ 67,873  
Maturity date         Nov. 30, 2022            
Ownership percentage         6.50%            
BHK Co Development Agreement [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Loan agreement, description       The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.              
BioLite Japan [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Interest rate percentage 0.00%                    
Outstanding advance         $ 0 150,000          
BioFirst [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Interest rate         1.00%            
Discount of stock price         12.00%            
Balance of outstanding loans         $ 188,753 147,875          
Accrued interest         40,878 40,878          
Jiangs [Member]                      
Related Parties Transactions (Details) [Line Items]                      
Outstanding advance         $ 19,789 $ 18,750